SCHEMBL1346003

SCHEMBL1346003

Nc1ccc2c(S(N)(=O)=O)cccc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 9/20 0.63
CA1 P00915 7/20 0.63
CA9 Q16790 6/20 0.63
PLAU P00749 1/20 0.56
ATIC P31939 1/20 0.49
HTR6 P50406 1/20 0.49
NSD2 O96028 1/20 0.47
DUSP3 P51452 1/20 0.47
PTPN5 P54829 1/20 0.47
CASP6 P55212 1/20 0.47
PTPN11 Q06124 1/20 0.47
CDK2 P24941 1/20 0.47
CA12 O43570 3/20 0.46
CA4 P22748 3/20 0.46
CA14 Q9ULX7 2/20 0.46
CA6 P23280 2/20 0.44
CYP2C9 P11712 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA5B Q9Y2D0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30440356 1.00 CA2 (0.63) CA2CA1CA9PLAUATIC
SCHEMBL29516390 0.85 PLAU (0.56) CA2CA1CA9PLAUATIC
SCHEMBL342865 0.85 PLAU (0.56) CA2CA1CA9PLAUATIC
SCHEMBL3849624 0.84 PLAU (0.55) CA2CA1CA9PLAUATIC
SCHEMBL8494394 0.84 PLAU (0.50) CA2CA1CA9PLAUATIC
SCHEMBL3849618 0.82 HTR6 (0.50) CA2CA1CA9PLAUATIC
SCHEMBL6562190 0.82 PLAU (0.49) CA2CA1CA9PLAUATIC
SCHEMBL1805507 0.81 CA2 (0.63) CA2CA1CA9ATICHTR6
SCHEMBL1807861 0.80 CA2 (0.61) CA2CA1CA9ATICHTR6
SCHEMBL1805508 0.80 CA2 (0.61) CA2CA1CA9ATICHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1779117-B1 METHODS FOR MEASURING ADAMTS13 ACTIVITY ON THE SURFACE OF PLATELETS AMERICAN DIAGNOSTICA INC (US) 2010-05-19 EP claimed
EP-1779117-A4 METHODS FOR MEASURING ADAMTS13 ACTIVITY AND PROTEIN ON PLATELETS AND IN PLASMA AMERICAN DIAGNOSTICA INC (US) 2008-02-20 EP claimed
US-7270976-B2 Methods for measuring ADAMTS13 activity and protein on platelets and in plasma AMERICAN DIAGNOSTICA, INC. (US) 2007-09-18 US claimed
EP-1779117-A1 METHODS FOR MEASURING ADAMTS13 ACTIVITY AND PROTEIN ON PLATELETS AND IN PLASMA American Diagnostica Inc. (US) 2007-05-02 EP claimed
WO-2006019379-A1 METHODS FOR MEASURING ADAMTS13 ACTIVITY AND PROTEIN ON PLATELETS AND IN PLASMA AMERICAN DIAGNOSTICA INC. (US) 2006-02-23 WO claimed
US-20060014233-A1 Methods for measuring ADAMTS13 activity and protein on platelets and in plasma BIOMEDICA DIAGNOSTICS INC. (CA) 2006-01-19 US claimed
EP-1007078-A4 PEPTIDOMIMETICS CONTAINING 6-PEPTIDYLAMINO-1-NAPHTHALENESULFONAMIDE MOIETIES BUTENAS SAULIUS (US) 2002-11-13 EP claimed
US-6194143-B1 MEASUREMENT ACTIVITY BY MONITORING SUBSTRATE CLEAVAGE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2001-02-27 US claimed
EP-1007078-A1 PEPTIDOMIMETICS CONTAINING 6-PEPTIDYLAMINO-1-NAPHTHALENESULFONAMIDE MOIETIES Butenas, Saulius (US) 2000-06-14 EP claimed
EP-0948640-A2 IMPROVED SUBSTRATES FOR HUMAN CYTOMEGALOVIRUS PROTEASE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1999-10-13 EP claimed
WO-1998022125-A9 PEPTIDOMIMETICS CONTAINING 6-PEPTIDYLAMINO-1-NAPHTHALENESULFONAMIDE MOIETIES 1998-10-08 WO claimed
WO-1998029562-A2 IMPROVED SUBSTRATES FOR HUMAN CYTOMEGALOVIRUS PROTEASE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1998-07-09 WO claimed
WO-1998022125-A1 PEPTIDOMIMETICS CONTAINING 6-PEPTIDYLAMINO-1-NAPHTHALENESULFONAMIDE MOIETIES BUTENAS SAULIUS (US) 1998-05-28 WO claimed
US-20250389737-A1 FACTOR Xa REAGENT INSTR LABORATORY CO (US) 2025-12-25 US disclosed
EP-4667582-A1 FACTOR XA REAGENT Instrumentation Laboratory Company (US) 2025-12-24 EP disclosed
US-20250361322-A1 ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND RELATED METHODS ICONIC THERAPEUTICS LLC (US) 2025-11-27 US disclosed
EP-0065595-A2 Water-soluble triazine compounds, their preparation and their use BAYER AG (DE) 1982-12-01 EP disclosed
EP-0002041-A1 Processes for synthesizing bisazomethine-bisazo pigments CIBA-GEIGY AG (CH) 1979-05-30 EP disclosed
US-4086223-A Asymmetrical 1:2-chromium complex azo dyestuffs CIBA-GEIGY AG (CH) 1978-04-25 US disclosed
US-4083844-A Phenylazo orthocyano phenylazo or orthocyano phenylazo phenylazo containing dyestuffs BAYER AKTIENGESELLSCHAFT (DT) 1978-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250389737-A1 FACTOR Xa REAGENT F9, F11, TFPI CA2 2625/4885CA1 1458/4885CA9 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.